ROCHESTER, MN — Inappropriate dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for atrial fibrillation (AF) was common in a large US cohort study, including inappropriate dosage ...

A common scenario: a patient presents with new-onset atrial fibrillation (AF) and multiple risk factors for stroke. Everyone agrees to use anticoagulant therapy to reduce the risk of stroke. The ...

Patients with nonvalvular atrial fibrillation treated with non-vitamin K oral anticoagulants (NOACs) have a heightened risk of major bleeding when also treated with other medications, including ...

Uninterrupted treatment with novel oral anticoagulants during catheter ablation of atrial fibrillation is safe, suggests new research. Continuation of NOAC therapy was not associated with ...

In patients with atrial fibrillation undergoing PCI, antithrombotic regimens involving a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) should be avoided, whereas use of a non-VKA ...

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

BOSTON -- Lower adherence to non-vitamin K antagonist oral anticoagulant (NOACs) might wipe out the advantage over warfarin (Coumadin), according to a large real-world observational study. In an ...

(HealthDay News) — Non-vitamin K antagonist oral anticoagulants (NOACs) have been adopted into practice and are more frequently prescribed than vitamin K antagonists (VKAs) in the Global Registry on ...

Atrial fibrillation is a common arrhythmia. It affects the atria, and it increases the risk of thromboembolic events—in particular, ischemic stroke and systemic embolization. The GLORIA-AF Registry is ...